These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 21724440)

  • 1. [Pathogen reduction for platelets: available techniques and recent developments].
    Andreu G
    Transfus Clin Biol; 2011 Aug; 18(4):444-62. PubMed ID: 21724440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathogen reduction of blood components.
    Solheim BG
    Transfus Apher Sci; 2008 Aug; 39(1):75-82. PubMed ID: 18602343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics of the THERAFLEX UV-Platelets pathogen inactivation system - an update.
    Seghatchian J; Tolksdorf F
    Transfus Apher Sci; 2012 Apr; 46(2):221-9. PubMed ID: 22365926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pathogen inactivation in platelet concentrates: the French experience].
    Cazenave JP
    Transfus Clin Biol; 2011 Aug; 18(4):478-84. PubMed ID: 21719338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathogen-reduction systems for blood components: the current position and future trends.
    Seghatchian J; de Sousa G
    Transfus Apher Sci; 2006 Dec; 35(3):189-96. PubMed ID: 17110168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogen reduction: state of reflection in Ireland.
    Murphy WG
    Transfus Clin Biol; 2011 Aug; 18(4):488-90. PubMed ID: 21803629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pathogen inactivation of platelets: organization consequences for platelet transfusion].
    Chavarin P; DePutter C; Boussoulade F; Acquart S; Vidal M; Argaud C; Fabrigli P; Garraud O
    Transfus Clin Biol; 2011 Aug; 18(4):472-7. PubMed ID: 21783400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on the use of pathogen-reduced human plasma and platelet concentrates.
    Seltsam A; Müller TH
    Br J Haematol; 2013 Aug; 162(4):442-54. PubMed ID: 23710899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pathogen reduction for platelets: a debate].
    Moncharmont P; Py JY
    Transfus Clin Biol; 2011 Aug; 18(4):498-501. PubMed ID: 21715209
    [No Abstract]   [Full Text] [Related]  

  • 10. Implementation of the INTERCEPT Blood System for Platelets into routine blood bank manufacturing procedures: evaluation of apheresis platelets.
    Janetzko K; Lin L; Eichler H; Mayaudon V; Flament J; Klüter H
    Vox Sang; 2004 May; 86(4):239-45. PubMed ID: 15144528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on pathogen reduction technology for therapeutic plasma: an overview.
    Solheim BG; Seghatchian J
    Transfus Apher Sci; 2006 Aug; 35(1):83-90. PubMed ID: 16934528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogen inactivation of Leishmania donovani infantum in plasma and platelet concentrates using riboflavin and ultraviolet light.
    Cardo LJ; Rentas FJ; Ketchum L; Salata J; Harman R; Melvin W; Weina PJ; Mendez J; Reddy H; Goodrich R
    Vox Sang; 2006 Feb; 90(2):85-91. PubMed ID: 16430665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction.
    Kerkhoffs JL; van Putten WL; Novotny VM; Te Boekhorst PA; Schipperus MR; Zwaginga JJ; van Pampus LC; de Greef GE; Luten M; Huijgens PC; Brand A; van Rhenen DJ;
    Br J Haematol; 2010 Jul; 150(2):209-17. PubMed ID: 20507310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates.
    Perez-Pujol S; Tonda R; Lozano M; Fuste B; Lopez-Vilchez I; Galan AM; Li J; Goodrich R; Escolar G
    Transfusion; 2005 Jun; 45(6):911-9. PubMed ID: 15934989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of random versus apheresis platelet concentrates.
    Andreu G; Vasse J; Sandid I; Tardivel R; Semana G
    Transfus Clin Biol; 2007 Dec; 14(6):514-21. PubMed ID: 18417401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of antibody formation to platelet neoantigens after transfusion of riboflavin and ultraviolet light-treated platelet concentrates.
    Ambruso DR; Thurman G; Marschner S; Goodrich RP
    Transfusion; 2009 Dec; 49(12):2631-6. PubMed ID: 19694996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemostatic function of buffy coat platelets in additive solution treated with pathogen reduction technology.
    Ostrowski SR; Bochsen L; Windeløv NA; Salado-Jimena JA; Reynaerts I; Goodrich RP; Johansson PI
    Transfusion; 2011 Feb; 51(2):344-56. PubMed ID: 20723169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New technologies for the inactivation of infectious pathogens in cellular blood components and the development of platelet substitutes.
    Corash L
    Baillieres Best Pract Res Clin Haematol; 2000 Dec; 13(4):549-63. PubMed ID: 11102276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein quality in Mirasol pathogen reduction technology-treated, apheresis-derived fresh-frozen plasma.
    Smith J; Rock G
    Transfusion; 2010 Apr; 50(4):926-31. PubMed ID: 20051060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelet function assessed by shear-induced deposition of split triple-dose apheresis concentrates treated with pathogen reduction technologies.
    Picker SM; Schneider V; Gathof BS
    Transfusion; 2009 Jun; 49(6):1224-32. PubMed ID: 19220821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.